This decreased stromal CD26 staining tended to be associated with poorer outcomes for breast cancer patients with tumors rich in stromal myofibroblasts than did moderately and significantly positive stromal CD26 staining (Figure 1E). This evidence concerns the gene DPP4 and breast carcinoma.